From intestinal dysbiosis to alcohol-associated liver disease

키워드

참고문헌 (114)

1. "Alcohol Facts and Statistics"[URL]
2. Teschke R, "Alcoholic liver disease : current mechanistic aspects with focus on their clinical relevance", Biomedicines, 7, pp.68~ (2019)
3. Rehm J, "Global burden of alcoholic liver diseases", J Hepatol, 59, pp.160~168 (2013)
4. Bagnardi V, "Alcohol consumption and site-specific cancer risk : a comprehensive dose-response meta-analysis", Br J Cancer, 112, pp.580~593 (2015)
5. Piano MR, "Alcohol’s effects on the cardiovascular system", Alcohol Res, 38, pp.219~241 (2017)
6. Yadav D, "The epidemiology of pancreatitis and pancreatic cancer", Gastroenterology, 144, pp.1252~1261 (2013)
7. Udoh US, "Genetic deletion of the circadian clock transcription factor BMAL1 and chronic alcohol consumption differentially alter hepatic glycogen in mice", Am J Physiol Gastrointest Liver Physiol, 314, pp.G431~G447 (2017)
8. Barr T, "Opposing effects of alcohol on the immune system", Prog Neuropsychopharmacol Biol Psychiatry, 65, pp.242~251 (2016)
9. Bluemel S, "Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota", Am J Physiol Gastrointest Liver Physiol, 311, pp.G1018~G1036 (2016)
10. Brenner DA, "Role of gut microbiota in liver disease", J Clin Gastroenterol, 49(Suppl 1(0 1)), pp.S25~S27 (2015)
11. Engen PA, "The gastrointestinal microbiome : alcohol effects on the composition of intestinal microbiota", Alcohol Res, 37, pp.223~236 (2015)
12. Seitz HK, "Alcoholic liver disease", Nat Rev Dis Primers, 4, pp.16~ (2018)
13. Avila MA, "Recent advances in alcohol-related liver disease(ALD) : summary of a gut round table meeting", Gut, 69, pp.764~780 (2020)
14. Sarin SK, "Microbiome as a therapeutic target in alcohol-related liver disease", J Hepatol, 70, pp.260~272 (2019)
15. Bishehsari F, "Alcohol and gut-derived inflammation", Alcohol Res, 38, pp.163~171 (2017)
16. Sommer F, "The resilience of the intestinal microbiota influences health and disease", Nat Rev Microbiol, 15, pp.630~638 (2017)
17. Canesso MCC, "Comparing the effects of acute alcohol consumption in germ-free and conventional mice : the role of the gut microbiota", BMC Microbiol, 14, pp.240~ (2014)
18. Hartmann P, "Gut microbiota in liver disease : too much is harmful, nothing at all is not helpful either", Am J Physiol Gastrointest Liver Physiol, 316, pp.G563~G573 (2019)
19. Yan AW, "Enteric dysbiosis associated with a mouse model of alcoholic liver disease", Hepatology, 53, pp.96~105 (2011)
20. Mutlu EA, "Colonic microbiome is altered in alcoholism", Am J Physiol Gastrointest Liver Physiol, 302, pp.G966~G978 (2012)
21. Chen P, "Microbiota protects mice against acute alcohol-induced liver injury", Alcohol Clin Exp Res, 39, pp.2313~2323 (2015)
22. Hendrikx T, "Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice", Gut, 68, pp.1504~1515 (2019)
23. Adachi Y, "Antibiotics prevent liver injury in rats following long-term exposure to ethanol", Gastroenterology, 108, pp.218~224 (1995)
24. Rios-Covian D, "Shaping the metabolism of intestinal Bacteroides population through diet to improve human health", Front Microbiol, 8, pp.376~ (2017)
25. den Besten G, "The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism", J Lipid Res, 54, pp.2325~2340 (2013)
26. d’Hennezel E, "Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling", mSystems, 2, pp.e00046~17 (2017)
27. Naito Y, "A next-generation beneficial microbe : Akkermansia muciniphila", J Clin Biochem Nutr, 63, pp.33~35 (2018)
28. Xu Y, "Function of Akkermansia muciniphila in obesity : interactions with lipid metabolism, immune response and gut systems", Front Microbiol, 11, pp.219~ (2020)
29. Leclercq S, "Role of inflammatory pathways, blood mononuclear cells, and gutderived bacterial products in alcohol dependence", Biol Psychiatry, 76, pp.725~733 (2014)
30. Llopis M, "Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease", Gut, 65, pp.830~ (2016)
31. Duan Y, "Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease", Nature, 575, pp.505~511 (2019)
32. Lang S, "Cytolysin-positive Enterococcus faecalis is not increased in patients with non-alcoholic steatohepatitis", Liver International, 40, pp.860~865 (2020)
33. Garcia-Tsao G., "Prophylactic antibiotics in cirrhosis: are they promoting or preventing infections?", Clin Liver Dis (Hoboken), 14, pp.98~102 (2019)
34. Yan K, "Novel prevention strategies for bacterial infections in cirrhosis", Expert Opin Pharmacother, 17, pp.689~701 (2016)
35. Fernández J, "Antibiotic prophylaxis in cirrhosis : good and bad", Hepatology, 63, pp.2019~2031 (2016)
36. Bode C, "Effect of treatment with paromomycin on endotoxemia in patients with alcoholic liver disease--a double-blind, placebo-controlled trial", Alcohol Clin Exp Res, 21, pp.1367~1373 (1997)
37. Soni H, "Antibiotics for prophylaxis of spontaneous bacterial peritonitis : systematic review & Bayesian network meta-analysis", Hepatol Int, 14, pp.399~413 (2020)
38. Kaji K, "Rifaximin alleviates endotoxemia with decreased serum levels of soluble CD163 and mannose receptor and partial modification of gut microbiota in cirrhotic patients", Antibiotics(Basel), 9, pp.145~ (2020)
39. Zapater P, "Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis", Gastroenterology, 137, pp.1669~1679.e1 (2009)
40. Horvath A, "Changes in the intestinal microbiome during a multispecies probiotic intervention in compensated cirrhosis", Nutrients, 12, pp.1874~ (2020)
41. Macnaughtan J, "A double-blind, randomized placebo-controlled trial of probiotic Lactobacillus casei shirota in stable cirrhotic patients", Nutrients, 12, pp.1651~ (2020)
42. Vidot H, "Supplementation with synbiotics and", or branched chain amino acids in hepatic encephalopathy : a pilot randomised placebocontrolled clinical study, 2019, pp.11, 1810~
43. Xu J, "Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis : an updated meta-analysis of six randomized controlled trials", Hepatobiliary Pancreat Dis Int, 13, pp.354~360 (2014)
44. Pande C, "Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis : a double-blind placebo-controlled randomizedcontrolled trial", Eur J Gastroenterol Hepatol, 24, pp.831~839 (2012)
45. Stadlbauer V, "Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis", J Hepatol, 48, pp.945~951 (2008)
46. Saggere Muralikrishna Shasthry, "Fecal microbiota transplantation in alcohol related liver diseases", Clinical and Molecular Hepatology, 26(3), pp.294~301 (2020), 대한간학회[DOI]
47. Bajaj JS, "Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis", Gastroenterology, 156, pp.1921~1923.e3 (2019)
48. Agus A, "Gut microbiota regulation of tryptophan metabolism in health and disease", Cell Host Microbe, 23, pp.716~724 (2018)
49. Gao J, "Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism", Front Cell Infect Microbiol, 8, pp.13~ (2018)
50. Hendrikx T, "Indoles : metabolites produced by intestinal bacteria capable of controlling liver disease manifestation", J Intern Med, 286, pp.32~40 (2019)
51. Roager HM, "Microbial tryptophan catabolites in health and disease", Nat Commun, 9, pp.3294~ (2018)
52. Lamas B, "Aryl hydrocarbon receptor and intestinal immunity", Mucosal Immunol, 11, pp.1024~1038 (2018)
53. Sun M, "Tryptophan(Trp)modulates gut homeostasis via aryl hydrocarbon receptor(AhR)", Crit Rev Food Sci Nutr, 60, pp.1760~1768 (2020)
54. Rankin LC, "Complementarity and redundancy of IL-22-producing innate lymphoid cells", Nat Immunol, 17, pp.179~186 (2016)
55. Liang H, "Dietary Ltryptophan modulates the structural and functional composition of the intestinal microbiome in weaned piglets", Front Microbiol, 9, pp.1736~ (2018)
56. Krishnan S, "Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages", Cell Rep, 23, pp.1099~1111 (2018)
57. Cervantes-Barragan L, "Lactobacillus reuteri induces gut intraepithelial CD4+CD8αα+ T cells", Science, 357, pp.806~810 (2017)
58. Sakurai T, "Production of indole-3-lactic acid by bifidobacterium strains isolated fromhuman infants", Microorganisms, 7, pp.340~ (2019)
59. Zelante T, "Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22", Immunity, 39, pp.372~385 (2013)
60. Wilck N, "Salt-responsive gut commensal modulates TH17axis and disease", Nature, 551, pp.585~589 (2017)
61. Beaumont M, "The gut microbiota metabolite indole alleviates liver inflammation in mice", FASEB J, 32, pp.6681~6693 (2018)
62. Gao B, "Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in patients with alcoholic hepatitis", Hepatol Commun, 4, pp.1168~1182 (2020)
63. Natividad JM, "Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome", Cell Metab, 28, pp.737~749.e4 (2018)
64. Ji Y, "Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress", Nutrients, 11, pp.2062~ (2019)
65. Ngo VL, "A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage", Proc Natl Acad Sci U S A, 115, pp.E5076~E5085 (2018)
66. Liu Y, "Lipopolysaccharide downregulates macrophage-derived IL-22 to modulate alcohol-induced hepatocyte cell death", Am J Physiol Cell Physiol, 313, pp.C305~C313 (2017)
67. Sabat R, "Therapeutic opportunities of the IL-22-IL-22R1 system", Nat Rev Drug Discov, 13, pp.21~38 (2014)
68. Ki SH, "Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding : Role of signal transducer and activator of transcription 3", Hepatology, 52, pp.1291~1300 (2010)
69. Radaeva S, "Interleukin 22(IL-22)plays a protective role in T cell-mediated murine hepatitis : IL-22 is a survival factor for hepatocytes via STAT3 activation", Hepatology, 39, pp.1332~1342 (2004)
70. Zhou H, "Enhanced regeneration and hepatoprotective effects of Interleukin 22 fusion protein on a predamaged liver undergoing partial hepatectomy", J Immunol Res, 2018, pp.5241526~ (2018)
71. Hartmann P, "Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity", Am J Physiol Gastrointest Liver Physiol, 310, pp.G310~G322 (2016)
72. Brandl K, "Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?", Expert Rev Gastroenterol Hepatol, 9, pp.1069~1076 (2015)
73. Xing WW, "Interleukin-22protects against acute alcohol-induced hepatotoxicity in mice", Biosci Biotechnol Biochem, 75, pp.1290~1294 (2011)
74. Hu BL, "Interleukin-22ameliorates liver fibrosis through miR-200a", beta-catenin, 2016, pp.6, 36436~
75. Eidenschenk C, "Interleukin-10 in Health and Disease", pp.213~236 (2014), Springer
76. Xu MJ, "IL-22 ameliorates renal ischemia-reperfusion injury by targeting proximal tubule epithelium", J Am Soc Nephrol, 25, pp.967~977 (2014)
77. Arab JP, "An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis", Hepatology, 72, pp.441~453 (2020)
78. Gao B, "Combination therapy: new hope for alcoholic hepatitis?", Clin Res Hepatol Gastroenterol, 39(Suppl 1), pp.S7~S11 (2015)
79. Zindl CL, "IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis", Proc Natl Acad Sci U S A, 110, pp.12768~12773 (2013)
80. Hammer AM, "Interleukin-22 prevents microbial dysbiosis and promotes intestinal barrier regeneration following acute injury", Shock, 48, pp.657~665 (2017)
81. Sugimoto K, "IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis", J Clin Invest, 118, pp.534~544 (2008)
82. Okumura R, "Maintenance of intestinal homeostasis by mucosal barriers", Inflamm Regen, 38, pp.5~ (2018)
83. Shin JH, "Reg3 proteins as gut hormones?", Endocrinology, 160, pp.1506~1514 (2019)
84. Burger-van Paassen N, "Mucin muc2 deficiency and weaning influences the expression of the innate defense genes reg3β, reg3γ and angiogenin-4", PLoS One, 7, pp.e38798~ (2012)
85. Vaishnava S, "The antibacterial lectin RegIIIγ promotes the spatial segregation of microbiota and host in the intestine", Science, 334, pp.255~258 (2011)
86. Brandl K, "MyD88-mediated signals induce the bactericidal lectin RegIIIγ and protect mice against intestinal Listeria monocytogenes infection", J Exp Med, 204, pp.1891~1900 (2007)
87. van Ampting MT, "Intestinally secreted c-type lectin Reg3b attenuates Salmonellosis but not Listeriosis in mice", Infect Immun, 80, pp.1115~1120 (2012)
88. Wang L, "Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation", Cell Host Microbe, 19, pp.227~239 (2016)
89. Miki T, "The bactericidal activity of the C-type lectin RegIIIβ against gram-negative bacteria involves binding to lipid A", J Biol Chem, 287, pp.34844~34855 (2012)
90. Zhao D, "Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease", J Clin Invest, 128, pp.4970~4979 (2018)
91. Hanash AM, "Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease", Immunity, 37, pp.339~350 (2012)
92. Hartmann P, "Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice", Hepatology, 58, pp.108~119 (2013)
93. Chu H, "Gut microbiota, fatty liver disease, and hepatocellular carcinoma", Liver Res, 2, pp.43~51 (2018)
94. Stärkel P, "Bidirectional Communication between liver and gut during alcoholic liver disease", Semin Liver Dis, 36, pp.331~339 (2016)
95. Stärkel P, "Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease", Clin Sci (Lond), 132, pp.199~212 (2018)
96. Ponziani FR, "Bacterial translocation in patients with liver cirrhosis : physiology, clinical consequences, and practical implications", Expert Rev Gastroenterol Hepatol, 12, pp.641~656 (2018)
97. Lang S, "Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis", Hepatology, 71, pp.522~538 (2020)
98. Bajaj JS, "Altered profile of human gut microbiome is associated with cirrhosis and its complications", J Hepatol, 60, pp.940~947 (2014)
99. Fukui H, "Gut-liver axis in liver cirrhosis : how to manage leaky gut and endotoxemia", World J Hepatol, 7, pp.425~442 (2015)
100. Parlesak A, "Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease", J Hepatol, 32, pp.742~747 (2000)
101. Bluemel S, "Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice", Gut Microbes, 11, pp.265~275 (2020)
102. Hritz I, "The critical role of toll-like receptor(TLR)4 in alcoholic liver disease is independent of the common TLR adapter MyD88", Hepatology, 48, pp.1224~1231 (2008)
103. Llorente C, "Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus", Nat Commun, 8, pp.837~ (2017)
104. Alexopoulou A, "Bacterial translocation markers in liver cirrhosis", Ann Gastroenterol, 30, pp.486~497 (2017)
105. Meroni M, "Alcohol or gut microbiota : who is the guilty?", Int J Mol Sci, 20, pp.4568~ (2019)
106. Inokuchi S, "Tolllike receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice", Alcohol Clin Exp Res, 35, pp.1509~1518 (2011)
107. Hartmann P, "Alcoholic liver disease : the gut microbiome and liver cross talk", Alcohol Clin Exp Res, 39, pp.763~775 (2015)
108. Uesugi T, "Role of lipopolysaccharide-binding protein in early alcoholinduced liver injury in mice", J Immunol, 168, pp.2963~2969 (2002)
109. Schäfer C, "Concentrations of lipopolysaccharide-binding protein, bactericidal", permeabilityincreasing protein, soluble CD14 and plasma lipids in relation to endotoxaemia in patients with alcoholic liver disease, 2002, pp.37, 81~86
110. Fukui H, "Role of gut dysbiosis in liver diseases : what have we learned so far?", Diseases, 7, pp.58~ (2019)
111. Liu M, "Dioscin alleviates alcoholic liver fibrosis by attenuating hepatic stellate cell activation via the TLR4", MyD88, Sci Rep, pp.2015, 5[DOI]
112. Schaffert CS, "Alcohol metabolites and lipopolysaccharide : roles in the development and", or progression of alcoholic liver disease, 2009, pp.15, 1209~1218
113. Rahul Kumar, "Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma", Clinical and Molecular Hepatology, 26(2), pp.196~208 (2020), 대한간학회[DOI]
114. Arroyo V, "Acute-on-chronic liver failure in cirrhosis", Nat Rev Dis Primers, 2, pp.16041~ (2016)

관련 논문AI추천